Last updated: 11/07/2018 12:11:26

Treatment Pathways in an Inception Lupus Cohort in Atlantic Canada

GSK study ID
201363
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Treatment Pathways in an Inception Lupus Cohort in Atlantic Canada
Trial description: The objective of this study is to describe current treatment patterns and sequence of therapeutic agents for lupus based on data from an inception cohort of systemic lupus erythematosus (SLE) patients in Atlantic Canada.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Primary

Timeframe: 3 years

Secondary outcomes:

Secondary

Timeframe: 3 years

Exploratory

Timeframe: 3 years

Interventions:
  • Other: N/A
    • Enrollment:
    79
    Primary completion date:
    Not applicable
    Observational study model:
    Cohort
    Time perspective:
    Retrospective
    Clinical publications:
    John G Hanly, Amyn Sayani, Steve Doucette, Sandra Iczkovitz, Jorge Alfonso Ross Terres. Treatment pathways in an inception lupus cohort over the first three years. Lupus.2017;26(2):119-124.
    Medical condition
    Systemic Lupus Erythematosus
    Product
    belimumab
    Collaborators
    Not applicable
    Study date(s)
    July 2014 to July 2014
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    Not applicable
    Accepts healthy volunteers
    none
    • Diagnosed with SLE based on ACR classification criteria
    • Interval between diagnosis of SLE and enrollment in cohort of less than 12 months
    • None
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Diagnosed with SLE based on ACR classification criteria
    • Interval between diagnosis of SLE and enrollment in cohort of less than 12 months
    • Minimum of 3 years of follow-up from time of enrollment in cohort
    Exclusion criteria:
    • None

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    Clinical study report
    Available language(s): English
    Download document(s)
    Scientific result summary
    Available language(s): English
    Download document(s)
    Protocol
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2014-31-07

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website